Literature DB >> 21095258

Towards an immunosense vaccine to prevent toxoplasmosis: protective Toxoplasma gondii epitopes restricted by HLA-A*0201.

Hua Cong1, Ernest J Mui, William H Witola, John Sidney, Jeff Alexander, Alessandro Sette, Ajesh Maewal, Rima McLeod.   

Abstract

The ideal vaccine to protect against toxoplasmosis in humans would include antigens that elicit a protective T helper cell type 1 immune response, and generate long-lived IFN-γ-producing CD8(+) T cells. Herein, we utilized a predictive algorithm to identify candidate HLA-A02 supertype epitopes from Toxoplasma gondii proteins. Thirteen peptides elicited production of IFN-γ from PBMC of HLA-A02 supertype persons seropositive for T. gondii infection but not from seronegative controls. These peptides displayed high-affinity binding to HLA-A02 proteins. Immunization of HLA-A*0201 transgenic mice with these pooled peptides, with a universal CD4(+) epitope peptide called PADRE, formulated with adjuvant GLA-SE, induced CD8(+) T cell IFN-γ production and protected against parasite challenge. Peptides identified in this study provide candidates for inclusion in immunosense epitope-based vaccines.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21095258      PMCID: PMC3014376          DOI: 10.1016/j.vaccine.2010.11.015

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  42 in total

1.  Thiazole, oxadiazole, and carboxamide derivatives of artemisinin are highly selective and potent inhibitors of Toxoplasma gondii.

Authors:  Christopher P Hencken; Lorraine Jones-Brando; Claudia Bordón; Remo Stohler; Bryan T Mott; Robert Yolken; Gary H Posner; Lauren E Woodard
Journal:  J Med Chem       Date:  2010-05-13       Impact factor: 7.446

2.  Functional characterization of in vivo effector CD4(+) and CD8(+) T cell responses in acute Toxoplasmosis: an interplay of IFN-gamma and cytolytic T cells.

Authors:  Erik Jongert; Arnaud Lemiere; Jo Van Ginderachter; Stéphane De Craeye; Kris Huygen; Sushila D'Souza
Journal:  Vaccine       Date:  2010-01-29       Impact factor: 3.641

3.  Annual burden of ocular toxoplasmosis in the US.

Authors:  Jeffrey L Jones; Gary N Holland
Journal:  Am J Trop Med Hyg       Date:  2010-03       Impact factor: 2.345

4.  A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis.

Authors:  Sylvie Bertholet; Gregory C Ireton; Diane J Ordway; Hillarie Plessner Windish; Samuel O Pine; Maria Kahn; Tony Phan; Ian M Orme; Thomas S Vedvick; Susan L Baldwin; Rhea N Coler; Steven G Reed
Journal:  Sci Transl Med       Date:  2010-10-13       Impact factor: 17.956

5.  Computational immunology meets bioinformatics: the use of prediction tools for molecular binding in the simulation of the immune system.

Authors:  Nicolas Rapin; Ole Lund; Massimo Bernaschi; Filippo Castiglione
Journal:  PLoS One       Date:  2010-04-16       Impact factor: 3.240

6.  Outbreak of acquired ocular toxoplasmosis involving 248 patients.

Authors:  Manohar B Balasundaram; Raghuram Andavar; Manikandan Palaniswamy; Narendran Venkatapathy
Journal:  Arch Ophthalmol       Date:  2010-01

Review 7.  Why prevent, diagnose and treat congenital toxoplasmosis?

Authors:  Rima McLeod; Francois Kieffer; Mari Sautter; Tiffany Hosten; Herve Pelloux
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-03       Impact factor: 2.743

8.  Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice.

Authors:  Majid Golkar; Mohammad-Ali Shokrgozar; Sima Rafati; Karine Musset; Mehdi Assmar; Reza Sadaie; Marie-France Cesbron-Delauw; Corinne Mercier
Journal:  Vaccine       Date:  2007-03-09       Impact factor: 3.641

9.  Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines.

Authors:  Huynh-Hoa Bui; John Sidney; Wei Li; Nicolas Fusseder; Alessandro Sette
Journal:  BMC Bioinformatics       Date:  2007-09-26       Impact factor: 3.169

10.  NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11.

Authors:  Claus Lundegaard; Kasper Lamberth; Mikkel Harndahl; Søren Buus; Ole Lund; Morten Nielsen
Journal:  Nucleic Acids Res       Date:  2008-05-07       Impact factor: 16.971

View more
  28 in total

1.  Oral oocyst-induced mouse model of toxoplasmosis: effect of infection with Toxoplasma gondii strains of different genotypes, dose, and mouse strains (transgenic, out-bred, in-bred) on pathogenesis and mortality.

Authors:  J P Dubey; L R Ferreira; J Martins; Rima McLeod
Journal:  Parasitology       Date:  2011-11-14       Impact factor: 3.234

2.  The Toxoplasma gondii peptide AS15 elicits CD4 T cells that can control parasite burden.

Authors:  Harshita Satija Grover; Nicolas Blanchard; Federico Gonzalez; Shiao Chan; Ellen A Robey; Nilabh Shastri
Journal:  Infect Immun       Date:  2012-07-09       Impact factor: 3.441

Review 3.  Interferon-gamma- and perforin-mediated immune responses for resistance against Toxoplasma gondii in the brain.

Authors:  Yasuhiro Suzuki; Qila Sa; Marie Gehman; Eri Ochiai
Journal:  Expert Rev Mol Med       Date:  2011-10-04       Impact factor: 5.600

Review 4.  Advances in the study of HLA-restricted epitope vaccines.

Authors:  Lingxiao Zhao; Min Zhang; Hua Cong
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

5.  Unconventional Peptide Presentation by Major Histocompatibility Complex (MHC) Class I Allele HLA-A*02:01: BREAKING CONFINEMENT.

Authors:  Soumya G Remesh; Massimo Andreatta; Ge Ying; Thomas Kaever; Morten Nielsen; Curtis McMurtrey; William Hildebrand; Bjoern Peters; Dirk M Zajonc
Journal:  J Biol Chem       Date:  2017-02-08       Impact factor: 5.157

6.  Genetic Polymorphisms in Cytokine Genes in Colombian Patients with Ocular Toxoplasmosis.

Authors:  C A Naranjo-Galvis; A de-la-Torre; L E Mantilla-Muriel; L Beltrán-Angarita; X Elcoroaristizabal-Martín; R McLeod; N Alliey-Rodriguez; I J Begeman; C López de Mesa; J E Gómez-Marín; J C Sepúlveda-Arias
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

Review 7.  The CD8 T-cell road to immunotherapy of toxoplasmosis.

Authors:  Rajarshi Bhadra; Jason P Gigley; Imtiaz A Khan
Journal:  Immunotherapy       Date:  2011-06       Impact factor: 4.196

8.  Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii.

Authors:  Kamal El Bissati; Aziz A Chentoufi; Paulette A Krishack; Ying Zhou; Stuart Woods; Jitender P Dubey; Lo Vang; Joseph Lykins; Kate E Broderick; Ernest Mui; Yasuhiro Suzuki; Qila Sa; Stephanie Bi; Nestor Cardona; Shiv K Verma; Laura Fraczek; Catherine A Reardon; John Sidney; Jeff Alexander; Alessandro Sette; Tom Vedvick; Chris Fox; Jeffrey A Guderian; Steven Reed; Craig W Roberts; Rima McLeod
Journal:  JCI Insight       Date:  2016-09-22

9.  Interleukin-10 Serum Levels after Vaccination with In Vivo Prepared Toxoplasma gondii Excreted/Secreted Antigens.

Authors:  Seyed Hossein Abdollahi; Fateme Ayoobi; Hossein Khorramdelazad; Gholamhossein Hassanshahi; Behzad Nasiri Ahmadabadi; Mohammadtaghi Rezayati; Ali Ravary; Ali Shamsizadeh; Mohammad Kazemi Arababadi
Journal:  Oman Med J       Date:  2013-03

10.  Effectiveness of a novel immunogenic nanoparticle platform for Toxoplasma peptide vaccine in HLA transgenic mice.

Authors:  Kamal El Bissati; Ying Zhou; Debleena Dasgupta; Drew Cobb; Jitender P Dubey; Peter Burkhard; David E Lanar; Rima McLeod
Journal:  Vaccine       Date:  2014-04-13       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.